Houston (1)

Acute Myeloid Leukemia (1)

Acute Myeloid Leukemia in Remission (1)

FLT3 Gene Mutation (1)

Hematologic and Lymphocytic Disorder (1)

Minimal Residual Disease Persistence (1)

Therapy-Related Acute Myeloid Leukemia (1)

Recruiting (1)

phase 2 (1)

M.D. Anderson Cancer Center (1)

Genentech, Inc. (1)

National Cancer Institute (NCI) (1)

azacitidine (1)

venetoclax (1)

drug (1)

Other (1)

Interventional (1)

minimal residual disease persistence

Showing 1 - 1 of 1

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Recruiting

Dec 13, 2022